Daniel J. Lippis, who serves as CVP for TAVR at Edwards Lifesciences (NYSE:EW), carried out two linked equity transactions on April 6, 2026. Lippis sold 1,019 shares of Edwards Lifesciences common stock for a combined $82,522, at a weighted average sale price of $80.984 per share. The individual sale prices recorded ranged between $80.64 and $81.07.
On the same date, Lippis also exercised stock options to purchase 1,019 shares of Edwards common stock at an exercise price of $59.2567 per share, for a total option exercise cost of $60,382. Both the sale and the option exercise were executed pursuant to a pre-arranged Rule 10b5-1 trading plan that Lippis adopted on July 30, 2025.
Following these moves, Lippis' direct holdings in Edwards Lifesciences total 33,933.9103 shares. At the time of reporting, Edwards Lifesciences shares were trading at $81.19 and the company's market capitalization was cited as $46.8 billion.
Market analysis referenced alongside the transaction indicates that the stock appears fairly valued. Analyst price targets span a range from $84 to $110, reflecting differing expectations among sell-side coverage. For subscribers seeking additional company research, a dedicated Pro Research Report for Edwards Lifesciences is available within the InvestingPro platform, which covers this stock among more than 1,400 U.S. equities.
Separately, Edwards Lifesciences released its fourth-quarter 2025 financial results that reflected a mixed performance versus expectations. The company reported adjusted earnings per share of $0.58, falling short of analysts' consensus forecast of $0.62. Revenue for the quarter totaled $1.57 billion, exceeding the $1.55 billion forecast and representing 11.6% year-over-year growth. That revenue outperformance was noted as topping both Stifel's estimates and consensus expectations. Stifel has reiterated a Buy rating with a $110 price target.
In clinical developments, Edwards presented two-year data from the TRISCEND II trial related to its EVOQUE transcatheter tricuspid valve replacement system. The trial data showed lower all-cause mortality for patients treated with the EVOQUE system and reported significant improvements in health status and quality of life measures, with no additional device-related risk identified in the analysis.
The company also announced an expansion of its Every Heartbeat Matters program, with an objective to enable access to structural heart treatment for an additional 2 million patients by 2030. The announcement notes that since 2014 the initiative has reached over 4 million underserved patients globally.
Context and implications
The concurrent sale and option exercise executed by Lippis under a Rule 10b5-1 plan represent a common mechanism executives use to manage equity positions while maintaining compliance with insider trading rules. The timing and structure of these transactions, as disclosed, follow a pre-arranged schedule that can provide clarity to investors tracking insider activity.
Operationally, Edwards' quarter combined revenue strength with an earnings shortfall versus expectations, while its TRISCEND II results and expansion of patient-access programs provide clinical and strategic developments that market participants will weigh alongside valuation and analyst outlooks.
Data summary
- Insider: Daniel J. Lippis, CVP, TAVR
- Sale: 1,019 shares for $82,522; weighted average price $80.984; range $80.64 - $81.07
- Option exercise: 1,019 shares at $59.2567 per share; total cost $60,382
- Plan: Transactions under Rule 10b5-1 plan adopted July 30, 2025
- Post-transaction direct ownership: 33,933.9103 shares
- Market: Share price $81.19; market cap $46.8 billion
- Analyst price targets: $84 to $110
- Q4 2025: Adjusted EPS $0.58 vs. $0.62 expected; revenue $1.57 billion vs. $1.55 billion expected; revenue +11.6% YoY
- Clinical: TRISCEND II two-year data showing lower all-cause mortality and improved patient-reported outcomes for EVOQUE
- Corporate program: Every Heartbeat Matters expansion targeting 2 million more patients by 2030; program reached over 4 million since 2014